Additional file 1 of Prognostic significance of multiparametric flow cytometry minimal residual disease at two time points after induction in pediatric acute myeloid leukemia
Creators: name: Zheng, Yongzhi
name: Pan, Lili
name: Li, Jian
name: Feng, Xiaoqin
name: Li, Chunfu
name: Zheng, Mincui
name: Mai, Huirong
name: Yang, Lihua
name: He, Yingyi
name: He, Xiangling
name: Xu, Honggui
name: Wen, Hong
name: Le, Shaohua
Publisher: name: figshare
Year: 2024
Subjects: subject: Cell Biology
subject: Pharmacology
subject: Biotechnology
subject: Immunology
subject: FOS: Clinical medicine
subject: Biological Sciences not elsewhere classified
subject: Cancer
subject: Science Policy
subject: Hematology

description: Additional file 1: Supplementary Figure 1. Treatment schema for the C-HUANAN-AML 15 protocol. *Note: intermediate-risk patients with a sibling donor and high-risk patients were advised to undergo allo-HSCT; Children aged &lt;1 year had all chemotherapy doses reduced by 25%. HSCT, hematopoietic stem cell transplantation. Supplementary Figure 2. EFS by MFC-MRD status after the first course of induction and before the start of consolidation. According to MFC-MRD levels, patients were stratified into three MFC-MRD-based groups (&lt; 0.01%, 0.01%–0.1%, and ≥ 0.1%). (a) EFS by MFC-MRD status after the first course of induction. (b) EFS by MFC-MRD status before the start of consolidation. EFS, event-free survival; MFC, multiparametric flow cytometry; MRD, minimal residual disease. Supplementary Figure 3. Survival probability by morphological response after the first course of induction and before the start of consolidation. According to the morphological response, patients were stratified into two morphology-based groups (CR; non-CR). EFS (a), OS (b), and CIR (c) according to morphological response after the first induction course; EFS (d), OS (e), and CIR (f) according to morphological response before start of consolidation. EFS, event-free survival; OS, overall survival; CIR, cumulative incidence of relapse; MFC, multiparametric flow cytometry; MRD, minimal residual disease. Supplementary Figure 4. Survival probability by MFC-MRD status in a separate analysis of patients with ≥5% or &lt;5% blasts, based on morphology after the first induction course. According to MFC-MRD levels, patients were stratified into two MFC-MRD-based groups (MRD &lt; 0.1%; MRD ≥ 0.1%). EFS (a), OS (b), and CIR (c) according to MFC-MRD level in a separate analysis of patients with &lt;5% blasts based on morphology after the first induction course (EFS: 38.5 ± 13.5% versus 45.0 ± 6.9%, P = 0.603; OS: 50.5 ± 7.5% versus 75.2 ± 12.6%, P = 0.280; CIR: 34.7 ± 7.9% versus 29.3 ± 14.3%, P = 0.704). EFS (d), OS (e), and CIR (f) according to MFC-MRD level in a separate analysis of patients with ≥5% blasts based on morphology after the first induction course (EFS: 70.0 ± 4.4% versus 72.8 ± 2.7%, P = 0.744; OS: 75.8 ± 4.2% versus 80.1 ± 2.5%, P = 0.474; CIR: 25.5 ± 4.4% versus 20.6 ± 2.6%, P = 0.388). EFS, event-free survival; OS, overall survival; CIR, cumulative incidence of relapse; MFC, multiparametric flow cytometry; MRD, minimal residual disease. Supplementary Figure 5. Survival probability by MFC-MRD status before the start of consolidation in a separate analysis of patients with different common genetic abnormalities. According to MFC-MRD levels, patients were stratified into two MFC-MRD-based groups (MRD &lt; 0.1%; MRD ≥ 0.1%). EFS according to MFC-MRD before starting consolidation in a separate analysis of patients with KMT2A-rearrangement (a), RUNX1-RUNX1T1 (b), FLT3-ITD mutation (c), and ASXL1 mutation (d). EFS, event-free survival; MFC, multiparametric flow cytometry; MRD, minimal residual disease. Supplementary Table 1. Number of patients recruited at each center. Supplementary Table 2. Characteristics of the patients. Supplementary Table 3. Prognostic risk systems in the C-HUANAN-AML15 protocol. Supplementary Table 4. Antibody panel used for immunophenotype studies at diagnosis. Supplementary Table 5. List of hospitals for MFC-MRD detection at the two MFC core hubs. Supplementary Table 6. Most common five-color combinations used to assess MRD after the first and second induction courses (chnam MRD panel).